Order Information
Contact us
Insert title here
Featured Products
HY-10005  |  Flavopiridol
HY-10008  |  SNS-032
HY-10012  |  AZD-5438
HY-10014  |  R547
HY-10032  |  PF 477736
HY-10087  |  Navitoclax
HY-10128  |  ZM-447439
HY-10161  |  Tozasertib
HY-10180  |  MLN8054
HY-10192  |  NVP-TAE 684
HY-10228  |  Motesanib
HY-10249  |  GSK-690693
HY-10355  |  AKT inhibitor VIII
HY-10358  |  MK 2206 (dihydrochloride)
HY-10992  |  AZD-7762
HY-10997  |  PCI-32765
HY-11001  |  PHA-793887
HY-11002  |  CP-466722
HY-11007  |  GNF-2
HY-11009  |  CGP60474


 (Synonyms  AZD2281;KU0059436)
763113-22-0  Technical Data: Price and Availability of  Cas No:763113-22-0

Cas : 763113-22-0 M.Wt: 434.4628
Cas : 763113-22-0 Formula: C24H23FN4O3
Cas : 763113-22-0 Purity: >98 %
Cas : 763113-22-0 Storage: at 20℃ 2 years
Cas : 763113-22-0 Solubility: DMSO: 29 mg/mL
Cas : 763113-22-0 Name: Olaparib
1g/$250 In-stock
2g/$450 In-stock
5g/$850 In-stock
10mg/$50 In-stock
10g/$1600 In-stock
50mg/$70 In-stock
100mg/$90 In-stock
200mg/$120 In-stock
500mg/$180 In-stock
1g Get quote
5g Get quote
>10g Get quote
We match the lowest price on market.
We offer a substantial discount on larger orders,please
inquire via sales@chemexpress.cn
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
Online Inquiry
763113-22-0  Data Sheet:
Introduction of 763113-22-0 :
Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively. IC50 & Target: IC50: 5/1 nM (PARP-1/2)[1] In Vitro: Olaparib (AZD2281) is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Olaparib is applied to SW620 cell lysates, and identified the IC50 for PARP-1 inhibition to be around 6 nM and the total ablation of PARP-1 activity to be at concentrations of 30?100 nM[1]. In Vivo: Animals bearing SW620 xenografted tumors are treated with Olaparib (10 mg/kg, p.o.) in combination with Temozolomide (TMZ) (50 mg/kg, p.o.) once daily for 5 consecutive days, after which the tumors are left to grow out[1]. Olaparib increases vascular perfusion in Calu-6 tumors established in a DWC model. Administration of olaparib(50 mg/kg, p.o.) as a single agent (top panel) or in combination with radiation (bottom panel) results in an increase in fluorescence intensity in the Calu-6 tumors[2].
References on 763113-22-0 :

Keywords: buy Olaparib | Olaparib Supplier | purchase Olaparib | Olaparib cost | Olaparib manufacturer | order Olaparib | Olaparib distributor | Olaparib structure
buy 763113-22-0 | 763113-22-0 Supplier | purchase 763113-22-0 | 763113-22-0 cost | 763113-22-0 manufacturer | order 763113-22-0 | 763113-22-0 distributor | 763113-22-0 structure
Insert title here
Products are for research use only. Not for human use. We do not sell to patients.           Copyright © 2009 Haoyuan Chemexpress All Rights Reserved
ADDRESS: 6/F, No. 2 Building, No. 720,Cailun Road, Shanghai, P.R.China  
86-21-58998590   FAX: 86-21-53700326, 86-21-58998590   E-mail: sales@chemexpress.cn